报价延迟最少15分钟:2025/07/16 16:11 EDT
盘后时段
|
||||
|
10.65 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.65
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.26/2.06
|
|
企业价值
1.01B
|
| 资产负债 |
|
每股账面净值
0.76
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
169.12M
|
|
每股收益
0.02
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/16 16:11 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology. |
